-
Mashup Score: 0Nadofaragene Firadenovec Management in Real-World BCG-Unresponsive Bladder Cancer: A Case-based Discussion - Mark Tyson - 21 hour(s) ago
Mark Tyson presents a case-based discussion on BCG-unresponsive non-muscle invasive bladder cancer treatment options. He describes a 67-year-old man with recurrent T1 disease after BCG who refused cystectomy despite high-risk features including lymphovascular invasion. Dr. Tyson outlines multiple treatment options including gemcitabine-docetaxel, pembrolizumab, nadofaragene, and nogapendekin,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Advanced Imaging for Focal Therapy in Intermediate Risk Prostate Cancer - Matthew Cooperberg - 1 day(s) ago
Zachary Klaassen speaks with Matthew Cooperberg about the integration of OnQ™ Prostate assisted Focal One® Robotic HIFU for prostate cancer treatment. Dr. Cooperberg discusses how appropriate candidate selection for focal therapy has evolved, emphasizing that focal therapy should be viewed as an adjunct to active surveillance rather than an alternative to radical treatment. He explains that the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advanced imaging for #FocalTherapy in intermediate-risk #ProstateCancer. @dr_coops @UCSFCancer and @zklaassen_md @GACancerCenter discuss the integration of OnQ™ Prostate assisted Focal One® Robotic HIFU for prostate cancer treatment. #WatchNow > https://t.co/gTpjtow1VH https://t.co/B8qvFdpL0H
-
-
Mashup Score: 26
Patient-Specific 3D-VR Anatomical Modeling, DICOM Images, Patient-Specific 3D-VR Anatomical Modeling for Presurgical Planning Using DICOM Images and Open-Source Software, PSMA PET/CT, 99mTc-PSMA-I&S, salvage pelvic lymph node dissection.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software. #AuthorCommentary on UroToday, shows how PSMA PET + 3D Slicer boosts lesion localization & confidence in the OR > https://t.co/BLYLhF2FuI https://t.co/ETx7wyv4ov
-
-
Mashup Score: 7
Zachary Klaassen speaks with Pedro Barata about chemohormonal therapy and treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Barata traces the evolution from 2015 when CHAARTED first showed docetaxel plus ADT improved outcomes, particularly in high-volume disease, through subsequent trials demonstrating ARPIs also enhance survival regardless of disease volume. The…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
New treatments are changing the game for metastatic #ProstateCancer! Learn about the evolution of chemohormonal therapy & what's next in care from expert @PBarataMD @caseccc and @zklaassen_md @GACancerCenter > https://t.co/lpdcd6uNzQ #CancerResearch https://t.co/9h2ijitQVN
-
-
Mashup Score: 5PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis "Presentation" - Michael Hofman - 4 day(s) ago
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman presents the PRIMARY score for PSMA PET in prostate cancer diagnosis. He explains how PSMA PET complements MRI, preventing missed clinically significant cancers (17%) and details the five-point scoring system where 1-2 suggests benign and 3-5 indicates increasing cancer likelihood. Dr. Hofman discusses the PRIMARY2 trial testing whether PSMA…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
What's the role of Primary Score in #ProstateCancer diagnosis? @DrMHofman @PeterMacCC shares insights at #PSMAandBeyond2025! Watch to learn more about this innovative tool > https://t.co/Bug0TmsbHx @PSMAconference @PCFnews @UCLA @UCSF https://t.co/PsFBszKneC
-
-
Mashup Score: 10
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor dosimetry in PSMA therapy: A #VISION substudy analysis. @ProfKHerrmann joins Oliver Sartor, MD discussing tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in #ProstateCancer patients. #FullVideo on UroToday > https://t.co/igHM3XAkST https://t.co/eHnyrkT4Ie
-
-
Mashup Score: 22Can PSMA-Targeted Prostate Biopsy Detect Cancer When MRI-Guided Biopsy is Negative? "Presentation" - Wayne Brisbane - 5 day(s) ago
At the 2025 UCSF-UCLA PSMA Conference, Wayne Brisbane presents a phase I trial examining PSMA-targeted prostate biopsy following negative/discordant MRI biopsies. Among 39 patients with SUV max > 3, 41% had Grade Group 2+ cancer. Notably, eleven lesions were completely de novo PSMA findings, with anterior lesions predominating. He suggests PSMA provides valuable “second look” capabilities,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Can PSMA targeted prostate biopsy detect cancer when MRI guided biopsy is negative? @wayne_brisbane shares insights at #PSMAandBeyond2025! Watch to learn more about the potential of PSMA in prostate cancer diagnosis! #WatchNow on UroToday > https://t.co/5tgS3ERC3m @PSMAconference https://t.co/LZPOSfCcSX
-
-
Mashup Score: 12PRECISION Data Platform Reveals mCRPC Treatment Outcomes in Urology Practices - Neal Shore - 6 day(s) ago
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from over 12,000 mCRPC patients across five years, revealing that community urologists show strong preference for sipuleucel-T and radium-223 as first and second-line therapies, followed by ARPIs, with limited taxane use….
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Real-world insights into mCRPC treatment! Dr. Neal Shore @CURCMB and @zklaassen_md discuss data from the PRECISION platform, highlighting treatment outcomes in #urology practices. #WatchNow > https://t.co/RJsJoh2wEx https://t.co/4Q8N3jSgi8
-
-
Mashup Score: 37Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer - Marco Moschini - 7 day(s) ago
Ashish Kamat speaks with Marco Moschini about expanding active surveillance criteria for recurrent low-grade bladder cancer. Dr. Moschini presents his single-center retrospective study from San Raffaele Hospital analyzing outcomes among intermediate-risk non-muscle invasive bladder cancer patients based on IBCG risk stratification. These findings demonstrate that patients with zero risk factors…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Risk stratification for active surveillance in low and intermediate-risk #BladderCancer. @UroMoschini @SanRaffaeleMI and @UroDocAsh @MDAndersonNews discuss expanding active surveillance criteria for recurrent low-grade bladder cancer. #WatchNow > https://t.co/TlAeqUI8fI https://t.co/eRxIOCo7jc
-
-
Mashup Score: 6Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish - Beyond the Abstract - 11 day(s) ago
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Initial linguistic and cultural validation of the satisfaction survey for inflatable penile implant (SSIPI) in Spanish. #AuthorCommentary @LjubeticMD, and Jose Miguel Flores, MD, MHA share details on UroToday > https://t.co/EvyQBKDrAi https://t.co/KtVDMnqmLV
-
Real-world insights into managing BCG-unresponsive bladder cancer with nadofaragene firadenovec! @MarkTysonMD @MayoClinic and @zklaassen_md @GACancerCenter share expert guidance on this innovative treatment approach > https://t.co/x3Up0IcM7L https://t.co/lWTJBwj64M